Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00343109 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer
A Phase 2 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT00343109 is a Phase 2 study that has completed, run by University of Washington. The registered enrollment target is 38 participants.
The verdict
NCT00343109, a Phase 2 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
This phase II trial is studying how well vaccine therapy works in treating patients receiving trastuzumab for HER2-positive stage IIIB- IV breast cancer. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells
Interventions
- OTHER laboratory biomarker analysis
- PROCEDURE leukapheresis
- BIOLOGICAL sargramostim
- OTHER immunologic technique
- BIOLOGICAL HER-2/neu intracellular domain protein
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2004-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00343109
The ClinicalTrials.gov registry entry for NCT00343109 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00343109 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00343109 about?
NCT00343109 is a clinical study titled "Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer". This phase II trial is studying how well vaccine therapy works in treating patients receiving trastuzumab for HER2-positive stage IIIB- IV breast cancer. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells
What is the current status of trial NCT00343109?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2004-03.
What interventions are being tested in trial NCT00343109?
The interventions under investigation include: laboratory biomarker analysis (OTHER), leukapheresis (PROCEDURE), sargramostim (BIOLOGICAL), immunologic technique (OTHER), HER-2/neu intracellular domain protein (BIOLOGICAL).
Who is sponsoring clinical trial NCT00343109?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.